Sandoz Can't Pare Claim From Generic Remodulin Suit
Sandoz Inc. can't trim a claim from a patent suit over a proposed generic version of United Therapeutics Corp.'s hypertension drug Remodulin, after a New Jersey federal judge on Wednesday found...To view the full article, register now.
Already a subscriber? Click here to view full article